Zimmer Biomet Holdings, Inc.
NYSE:ZBHMedical - Devices
+$0.87 today
- Market cap
- $19.55B
- Beta
- 0.47
- P/E (TTM)
- 22.5
- EPS (TTM)
- $3.90
- Dividend yield
- 1.09%
Volume 2.34M
Average 2.28M
ZBH Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Zimmer Biomet Holdings, Inc.NYSE: ZBH
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables turns negative
Q2 FY2026 accounts receivables was -$38.5M, compared with $200K a year earlier. Trailing-twelve-month accounts receivables was -$132.7M. Over 3 fiscal years it compounded at -11.7% a year.
Context
- Accounts receivables amounted to 1.5% of revenue in FY2025, up 0.4 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near -$38.5M or moves back toward the trailing-twelve-month quarterly average of -$33.18M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (127.3M) USD
- Year-over-year change
- -41.9%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (127.3M) | -41.9% |
| FY2024 | 2024-12-31 | (89.7M) | -72.8% |
| FY2023 | 2023-12-31 | (51.9M) | +71.9% |
| FY2022 | 2022-12-31 | (184.7M) | -352.7% |
| FY2021 | 2021-12-31 | (40.8M) | — |
Accounts Receivables vs competitors
How ZBH compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +35.3% is the 6th highest of 10, against a peer median of +116.0%.
- Accounts receivables amounts to 1.6% of revenue for ZBH, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $402M USD | +166.2% | -21.1% | 2.0% | |
| LTM Jun 2026 | $293M USD | +144.2% | +6.9% | 1.4% | |
| LTM Jun 2026 | €288.18M EUR | -264.3% | -70.7% | 1.6% | |
| LTM Jul 2026 | $264M USD | +3.5% | -29.7% | 0.7% | |
| FY2025 | $175M USD | +116.0% | +19.3% | 2.8% | |
| LTM Jun 2026 | $137M USD | +182.0% | — | 0.5% | |
| LTM Jun 2026 | $132.7M USD | +35.3% | -11.7% | 1.6% | |
| LTM Jun 2026 | $82.5M USD | -197.5% | -35.1% | 1.3% | |
| LTM Jun 2026 | $18.5M USD | -85.5% | — | 0.4% | |
| LTM Mar 2026 | $5.26M USD | +166.0% | -38.3% | 0.6% | |
| Peer median (excluding ZBH) | — | +116.0% | -29.7% | 1.3% | |
Competitors are the stored peer set for ZBH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 445.5M | 291.2M | 1.03B | 905.2M | 705.1M |
| Depreciation & Amortization | 937.7M | 926.4M | 951.7M | 996.3M | 1.09B |
| Deferred Income Tax | (102.1M) | (64.4M) | (96.3M) | (47.7M) | (87.2M) |
| Stock-Based Compensation | 76M | 105M | 99.8M | 101M | 90.2M |
| Change in Working Capital | (134.2M) | (311.4M) | (396.2M) | (455.4M) | (104.9M) |
| Accounts Receivables | (40.8M) | (184.7M) | (51.9M) | (89.7M) | (127.3M) |
| Inventory | (8.4M) | (75.6M) | (240.4M) | 49.9M | 98.2M |
| Accounts Payables | 86.5M | 103M | (55.3M) | (322M) | 101.8M |
| Other Working Capital | (171.5M) | (154.1M) | (48.6M) | (93.6M) | (177.6M) |
| Other Non-Cash Items | 276.3M | 337.9M | (2.5M) | 0 | 100K |
| Operating Cash Flow | 1.5B | 1.28B | 1.58B | 1.5B | 1.7B |
| Capital Expenditures | (152M) | (217.6M) | (394.5M) | (356.8M) | (224.5M) |
| Acquisitions (Net) | 0 | (99.8M) | (134.9M) | (276.3M) | (1.39B) |
| Purchases of Investments | (273.6M) | (258.3M) | (311.7M) | (240.3M) | (300.5M) |
| Sales of Investments | 1.9M | 89.4M | 33.4M | 22.1M | 0 |
| Other Investing Activities | (88.3M) | (72.6M) | (74.6M) | (189.8M) | (57.5M) |
| Investing Cash Flow | (503.6M) | (529.2M) | (778.9M) | (888.1M) | (1.98B) |
| Debt Repayment | (1.06B) | (1.06B) | 54.6M | 536.3M | 1.03B |
| Common Stock Issued | 122.5M | 0 | 0 | 0 | 39.7M |
| Common Stock Repurchased | 0 | (126.4M) | (692.2M) | (868M) | (487M) |
| Dividends Paid | (200.1M) | (201.2M) | (200.9M) | (196M) | (190.3M) |
| Other Financing Activities | (173.4M) | 544.5M | 75M | 43.2M | (65.5M) |
| Financing Cash Flow | (1.31B) | (843.8M) | (763.5M) | (484.5M) | 326M |
| Effect of Forex Changes | (13.2M) | (14.5M) | 900K | (17.1M) | 19M |
| Net Change in Cash | (323.6M) | (102.8M) | 40.1M | 109.7M | 66.4M |
| Free Cash Flow | 1.35B | 1.07B | 1.19B | 1.14B | 1.47B |
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
Intrinsic Alpha fair value
Locked
Current Price
$103.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.